z-logo
open-access-imgOpen Access
Trichosporon asahii Urinary Tract Infection in a Patient with Severe COVID-19
Author(s) -
Verschoyle Cronyn,
John Howard,
Leslie Chiang,
Lisa W. Le,
Zandraetta Tims-Cook,
Alida M. Gertz
Publication year - 2021
Publication title -
case reports in infectious diseases
Language(s) - English
Resource type - Journals
eISSN - 2090-6625
pISSN - 2090-6633
DOI - 10.1155/2021/6841393
Subject(s) - medicine , voriconazole , urinary system , fluconazole , trichosporon , antibiotics , intensive care medicine , antifungal , dermatology , microbiology and biotechnology , biology , genetics , yeast
Trichosporon asahii is a yeast-like basidiomycete that is an emerging opportunistic infection in immunocompromised patients. Urinary tract infections due to T. asahii are rarely reported in the literature and typically seen only in immunocompromised patients. In addition to being immunocompromised, critically ill COVID-19 patients often have prolonged exposure to antibiotics, corticosteroids, and Foley catheters, which further increases their susceptibility to infection with T. asahii. There are limited case reports documenting successful treatment of T. asahii among hospitalized patients, particularly among COVID-19 patients, in the literature. Therefore, it is important that successful treatment regimens be reported. Here, we report a case of T. asahii urinary tract infection successfully treated with fluconazole and voriconazole in a 73-year-old male recovering from COVID-19. Urinary tract infections with T. asahii should be considered in persistently febrile COVID-19 patients with fungal urinary tract infections since prompt recognition and treatment can reduce the risk of disseminated disease and early mortality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom